They evaluated the medical records of 104 treatment-naïve advanced NSCLC patients with EGFR mutantion and BMs, 56 patients received both EGFR-TKIs and WBRT, and 48 patients received just -TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.